Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms
Sarah E. Turbett, Melis N. Anahtar, Anand S. Dighe, Wilfredo Garcia Beltran, Tyler E. Miller, Hannah C. Scott, Sienna Durbin, Maheetha Bharadwaj, Jason Thomas, Tasos Gogakos, Michael G. Astudillo, Jochen K. Lennerz, Eric Rosenberg, John A. Branda
Abstract
Sensitive and specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic assays are needed to inform diagnostic, therapeutic, and public health decision-making. We evaluated three commercial serologic assays as stand-alone tests and as components of two-test algorithms. Two nucleocapsid antibody tests (Abbott IgG and Roche total antibody) and one spike protein antibody test (DiaSorin IgG) were included. We assessed sensitivity using 128 serum samples from symptomatic PCR-confirmed coronavirus disease 2019 (COVID-19)-infected patients and specificity using 1,204 samples submitted for routine serology prior to COVID-19’s emergence, plus 64 pandemic-era samples from SARS-CoV-2 PCR-negative patients with respiratory symptoms.